# The Safety and Efficacy of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM

> **NCT02582814** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 151 (actual)

## Conditions studied

- Type 1 Diabetes Mellitus

## Interventions

- **DRUG:** Dapagliflozin 5 mg
- **DRUG:** Dapagliflozin 10mg

## Key facts

- **NCT ID:** NCT02582814
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-26
- **Primary completion:** 2017-06-15
- **Final completion:** 2017-06-15
- **Target enrollment:** 151 (ACTUAL)
- **Last updated:** 2019-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02582814

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02582814, "The Safety and Efficacy of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02582814. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*